RU2015143859A - Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира - Google Patents

Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира Download PDF

Info

Publication number
RU2015143859A
RU2015143859A RU2015143859A RU2015143859A RU2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A
Authority
RU
Russia
Prior art keywords
composition
bimatoprost
fat
release
deposits
Prior art date
Application number
RU2015143859A
Other languages
English (en)
Russian (ru)
Other versions
RU2015143859A3 (enExample
Inventor
Скотт М. Виткап
Дэвид Ф. ВУДВАРД
Патрик М. ХЬЮЗ
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2015143859A publication Critical patent/RU2015143859A/ru
Publication of RU2015143859A3 publication Critical patent/RU2015143859A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
RU2015143859A 2013-04-12 2014-04-09 Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира RU2015143859A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
US61/811,682 2013-04-12
PCT/US2014/033558 WO2014169075A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Publications (2)

Publication Number Publication Date
RU2015143859A true RU2015143859A (ru) 2017-05-16
RU2015143859A3 RU2015143859A3 (enExample) 2018-03-05

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015143859A RU2015143859A (ru) 2013-04-12 2014-04-09 Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира

Country Status (18)

Country Link
US (2) US20140308354A1 (enExample)
EP (2) EP2983663B1 (enExample)
JP (1) JP2016520561A (enExample)
KR (1) KR20150141972A (enExample)
CN (2) CN110840899A (enExample)
AU (2) AU2014250937A1 (enExample)
BR (1) BR112015025915A8 (enExample)
CA (1) CA2908731A1 (enExample)
CL (1) CL2015003023A1 (enExample)
DK (1) DK2983663T3 (enExample)
ES (1) ES2785382T3 (enExample)
IL (1) IL242006B (enExample)
MX (1) MX381097B (enExample)
MY (1) MY187802A (enExample)
RU (1) RU2015143859A (enExample)
SG (2) SG10201701938PA (enExample)
WO (1) WO2014169075A1 (enExample)
ZA (1) ZA201507217B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159427B1 (ko) * 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP7879845B2 (ja) * 2020-07-21 2026-06-24 アラーガン、インコーポレイテッド プロスタミドが高充填された眼内インプラント
EP4698184A1 (en) * 2023-04-18 2026-02-25 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
ES2379652T3 (es) 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
WO2005063205A2 (en) * 2003-12-22 2005-07-14 Aventis Pharmaceuticals Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
EP2595604B1 (en) 2010-07-21 2016-03-30 Allergan, Inc. Method of controlling initial drug release of sirna from sustained-release implants
ES2751681T3 (es) * 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
KR102159427B1 (ko) 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도

Also Published As

Publication number Publication date
MX381097B (es) 2025-03-12
CN110840899A (zh) 2020-02-28
MX2015014320A (es) 2015-12-08
EP3656375A1 (en) 2020-05-27
AU2019203214A1 (en) 2019-05-30
MY187802A (en) 2021-10-26
AU2014250937A1 (en) 2015-10-22
HK1221406A1 (en) 2017-06-02
KR20150141972A (ko) 2015-12-21
ES2785382T3 (es) 2020-10-06
SG10202109919PA (en) 2021-10-28
CA2908731A1 (en) 2014-10-16
US10682361B2 (en) 2020-06-16
DK2983663T3 (da) 2020-04-20
CN105101962A (zh) 2015-11-25
US20140308354A1 (en) 2014-10-16
AU2019203214B2 (en) 2020-10-29
JP2016520561A (ja) 2016-07-14
WO2014169075A1 (en) 2014-10-16
RU2015143859A3 (enExample) 2018-03-05
IL242006B (en) 2020-04-30
BR112015025915A2 (pt) 2017-07-25
CL2015003023A1 (es) 2016-06-10
BR112015025915A8 (pt) 2020-01-14
EP2983663A1 (en) 2016-02-17
EP2983663B1 (en) 2020-01-22
ZA201507217B (en) 2017-09-27
NZ712804A (en) 2021-02-26
SG10201701938PA (en) 2017-04-27
US20160339039A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
IL294463A (en) Methods for treating or preventing eye conditions
EA200970348A1 (ru) Новые инъецируемые депо-композиции и способ получения таких композиций
RU2011143860A (ru) Безфосфатный лекарственный препарат для лечения глаукомы
RU2014133501A (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
RU2017115563A (ru) Композиции и способы лечения дисфункции мейбомиевых желез
CA2907721A1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
AR080072A1 (es) Composicion farmaceutica solida con mejoradores y metodos para prepararla
RU2012155711A (ru) Жидкий назальный спрей, содержащий налтрексон в низкой дозе
AU2003222049A1 (en) Prostaglandin F2 alpha analogs in combination with antimicrobials for treating glaucoma
UA104945C2 (uk) Фармацевтична композиція лігандів рецепторів секретагогів гормону росту
EP3851130A4 (en) INJECTION FORMULATION WITH POLY-L-LACTIC ACID FILLER AND HYALURONIC ACID FILLER CONJUGATE AND METHOD OF MANUFACTURE THEREOF
AR120290A1 (es) Una forma de dosificación parenteral estable de acetato de cetrorelix
AU2017261303A1 (en) Ophthalmic compositions
SI3085381T1 (en) Orodispersible desmopressin to increase the initial sleep period without disturbing the nostrils
HRP20140676T1 (hr) Formulacije deoksikolne kiseline i njezinih soli
KR20030016418A (ko) 고안압증 및 녹내장의 치료를 위한 조성물
MX2021011727A (es) Composiciones y metodos para tratar enfermedades oculares.
US20100292156A1 (en) Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof
ES2764654T3 (es) Combinaciones de prostaglandinas y donantes de óxido nítrico
CN103596572A (zh) 水性眼用组合物
RU2016121401A (ru) Устойчивые при хранении лиофилизованные составы трипептидов
JP2016520561A5 (enExample)
PH12012501349A1 (en) Dp2 antagonist and uses thereof
WO2014183018A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY
JP2013515049A5 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210301